» Articles » PMID: 29264150

Prostate Chronic Inflammation Type IV and Prostate Cancer Risk in Patients Undergoing First Biopsy Set: Results of a Large Cohort Study

Overview
Journal Asian J Urol
Specialty Urology
Date 2017 Dec 22
PMID 29264150
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: In prostate specimens, chronic inflammatory infiltrate (CII) type IV has been detected, but its association with prostate cancer (PCa) is controversial. The aim of the present study is to investigate on associations of CII with PCa detection in patients undergoing prostate first biopsy set.

Methods: Ultrasound transrectal-guided biopsies by the transperineal approach were retrospectively evaluated in 441 consecutive patients. The study excluded patients who were in active surveillance, prostate specific antigen (PSA) ≥30 ng/mL, re-biopsies, incidental PCa after transurethral resection of the prostate (TURP), less than 14 cores or metastatic. Analysis of population and subpopulations (with or without PCa) was performed by statistical methods which included Mann-Whitney ( test), Kruskal-Wallis test, Chi-squared statistic, logistic regression. Multivariate logistic regression models predicting mean probability of PCa detection were established.

Results: PCa detection rate was 46.03%. Age, PSA, prostate volume (PV), prostate intraepithelial neoplasia (PIN) and CII were the significant independent predictors of PCa detection. PV (OR = 0.934) and CII (OR = 0.192) were both negative independent predictors. CII was a significant negative independent predictor in multivariate logistic regression models predicting the mean probability of PCa detection by age, PSA and PV. The inverse association of CII with PCa does not necessary mean protection because of PSA confounding.

Conclusion: In a population of patients undergoing prostate first biopsy set, CII was a strong negative independent predictor of PCa detection. CII type IV should be considered as an adjunctive parameter in re-biopsy or active surveillance protocols.

Citing Articles

Analysis of Inflammatory Features in Suspicious Lesions for Significant Prostate Cancer on Magnetic Resonance Imaging-Are They Mimickers of Prostate Cancer?.

Morote J, Celma A, Semidey M, Antolin A, Miro B, Mendez O Cancers (Basel). 2025; 17(1.

PMID: 39796682 PMC: 11718908. DOI: 10.3390/cancers17010053.


The Molecular Basis and Clinical Consequences of Chronic Inflammation in Prostatic Diseases: Prostatitis, Benign Prostatic Hyperplasia, and Prostate Cancer.

Oseni S, Naar C, Pavlovic M, Asghar W, Hartmann J, Fields G Cancers (Basel). 2023; 15(12).

PMID: 37370720 PMC: 10296711. DOI: 10.3390/cancers15123110.


Elevated prostate volume index and prostatic chronic inflammation reduce the number of positive cores at first prostate biopsy set: results in 945 consecutive patients.

Porcaro A, Tafuri A, Sebben M, Novella G, Processali T, Pirozzi M Int Braz J Urol. 2020; 46(4):545-556.

PMID: 32213210 PMC: 7239280. DOI: 10.1590/S1677-5538.IBJU.2019.0146.

References
1.
Konig J, Senge T, Allhoff E, Konig W . Analysis of the inflammatory network in benign prostate hyperplasia and prostate cancer. Prostate. 2004; 58(2):121-9. DOI: 10.1002/pros.10317. View

2.
Zhang W, Sesterhenn I, Connelly R, Mostofi F, Moul J . Inflammatory infiltrate (prostatitis) in whole mounted radical prostatectomy specimens from black and white patients is not an etiology for racial difference in prostate specific antigen. J Urol. 1999; 163(1):131-6. View

3.
Murphy C, McGurk M, Pettigrew J, Santinelli A, Mazzucchelli R, Johnston P . Nonapical and cytoplasmic expression of interleukin-8, CXCR1, and CXCR2 correlates with cell proliferation and microvessel density in prostate cancer. Clin Cancer Res. 2005; 11(11):4117-27. DOI: 10.1158/1078-0432.CCR-04-1518. View

4.
Palapattu G, Sutcliffe S, Bastian P, Platz E, De Marzo A, Isaacs W . Prostate carcinogenesis and inflammation: emerging insights. Carcinogenesis. 2004; 26(7):1170-81. DOI: 10.1093/carcin/bgh317. View

5.
Sindhwani P, Wilson C . Prostatitis and serum prostate-specific antigen. Curr Urol Rep. 2005; 6(4):307-12. DOI: 10.1007/s11934-005-0029-y. View